JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AstraZeneca PLC ADR

Geschlossen

73.59 -1.31

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

73.52

Max

73.74

Schlüsselkennzahlen

By Trading Economics

Einkommen

-923M

2.5B

Verkäufe

1B

15B

KGV

Branchendurchschnitt

27.832

34.393

Dividendenrendite

2.12

Gewinnspanne

16.947

Angestellte

94,300

EBITDA

-18M

5B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+24.72% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.12%

2.54%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

5.1B

231B

Vorheriger Eröffnungskurs

74.9

Vorheriger Schlusskurs

73.59

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

AstraZeneca PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Juli 2025, 08:08 UTC

Ergebnisse

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29. Juli 2025, 06:46 UTC

Ergebnisse

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

8. Aug. 2025, 10:51 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1. Aug. 2025, 11:10 UTC

Heiße Aktien

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29. Juli 2025, 11:02 UTC

Ergebnisse

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29. Juli 2025, 11:02 UTC

Ergebnisse

AstraZeneca 2Q EPS $1.58 >AZN.LN

29. Juli 2025, 11:01 UTC

Ergebnisse

AstraZeneca 2Q Rev $14.5B >AZN.LN

29. Juli 2025, 11:00 UTC

Ergebnisse

AstraZeneca Results: H1 and Q2 2025

29. Juli 2025, 08:00 UTC

Market Talk
Ergebnisse

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29. Juli 2025, 07:53 UTC

Market Talk
Ergebnisse

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29. Juli 2025, 07:26 UTC

Market Talk
Ergebnisse

AstraZeneca Shares Look Undervalued -- Market Talk

29. Juli 2025, 06:03 UTC

Ergebnisse

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29. Juli 2025, 06:03 UTC

Ergebnisse

AstraZeneca 2Q Total Revenue $14.46B

29. Juli 2025, 06:03 UTC

Ergebnisse

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29. Juli 2025, 06:03 UTC

Ergebnisse

AstraZeneca 2Q Core EPS $2.17

29. Juli 2025, 06:02 UTC

Ergebnisse

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29. Juli 2025, 06:02 UTC

Ergebnisse

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29. Juli 2025, 06:02 UTC

Ergebnisse

AstraZeneca Backs 2025 View

29. Juli 2025, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Rev $14.46B

29. Juli 2025, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Adj EPS $2.17

29. Juli 2025, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Pretax Pft $3.13B

29. Juli 2025, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Net Pft $2.45B

29. Juli 2025, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Oper Pft $3.51B

29. Juli 2025, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q EPS $1.57

28. Juli 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22. Juli 2025, 10:19 UTC

Market Talk

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22. Juli 2025, 09:34 UTC

Heiße Aktien

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9. Juli 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9. Juli 2025, 09:17 UTC

Heiße Aktien

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28. Mai 2025, 18:09 UTC

Ergebnisse

Heart Disease Could Be a Goner When These New -2-

Peer-Vergleich

Kursveränderung

AstraZeneca PLC ADR Prognose

Kursziel

By TipRanks

24.72% Vorteil

12-Monats-Prognose

Durchschnitt 93 USD  24.72%

Hoch 97 USD

Tief 85 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AstraZeneca PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 69.55Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.